Patents by Inventor Zhaolong Tong

Zhaolong Tong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12152051
    Abstract: A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: November 26, 2024
    Assignee: SHANGHAI DE NOVO PHARMATECH CO., LTD.
    Inventors: Zhaolong Tong, Ping Qin, Fengtao Liu, Jinglu Wang, Xiaolei Deng, Hongli Guo, Dawei Chen, Daxin Gao
  • Publication number: 20240299572
    Abstract: The present application relates to a nitrogen-containing compound, a conjugate containing said compound, and an application thereof. Specifically, the present application provides a compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof. The nitrogen-containing compound has a good regulating effect on TLR8 and can effectively treat, alleviate, and/or prevent various diseases caused by immunosuppression, such as a cancer or a viral infection.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 12, 2024
    Inventors: Zhaolong TONG, Man ZHANG, Heping YANG, Xiaohuan LIU, Longsheng WANG, Jicheng REN, Daxin GAO
  • Publication number: 20220041644
    Abstract: A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 10, 2022
    Inventors: Zhaolong TONG, Ping QIN, Fengtao LIU, Jinglu WANG, Xiaolei DENG, Hongli GUO, Dawei CHEN, Daxin GAO
  • Publication number: 20140378487
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: Zehong Wan, Xiaomin Zhang, Zhaolong Tong, Kai Long, Saiah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
  • Patent number: 8871928
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: October 28, 2014
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
  • Publication number: 20130178488
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Application
    Filed: September 20, 2011
    Publication date: July 11, 2013
    Inventors: Zehong WAN, Xiaomio Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman